[Risk profile of disease-modifying antirheumatic drugs: an update from the RABBIT register]

Overview
Related items

Abstract:

This article provides an overview of current results from the German biologics register RABBIT on the safety of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis. Collaborative data from the European biologics registries show no evidence for an overall increased risk of malignancy with TNF inhibitors. Venous thromboembolism occurs less frequently under TNF inhibitors than under conventional synthetic DMARDs. Regarding interleukin-6 inhibitors, the incidence of lower intestinal tract perforations is increased with tocilizumab and presents with atypical symptoms. There is no evidence of increased facial paresis with tocilizumab. Janus kinase inhibitors increase the risk for the occurrence of herpes zoster. New data on biosimilars suggest that they can be used with a comparable safety profile to originator drugs.

SEEK ID: https://ldh.drfz.imise.uni-leipzig.de/publications/83

DOI: 10.1055/a-1334-7609

Projects: RABBIT (Rheumatoid Arthritis - Observation of Biologic Therapies)

Publication type: Journal

Journal: Dtsch Med Wochenschr

Citation: Dtsch Med Wochenschr 146(15):998-1002

Date Published: 2021

URL: https://www.ncbi.nlm.nih.gov/pubmed/34344036

Registered Mode: imported from a bibtex file

Authors: K. Albrecht, A. Strangfeld

Help

Tree Split Graph

Submitter

Adrian Richter

Citation

Albrecht, K., & Strangfeld, A. (2021). Risikoprofil rheumatologische Basistherapie – ein Update aus dem RABBIT-Register. In DMW - Deutsche Medizinische Wochenschrift (Vol. 146, Issue 15, pp. 998–1002). Georg Thieme Verlag KG. https://doi.org/10.1055/a-1334-7609

Activity

Views: 43

Created: 15th Jul 2025 at 09:46

[Risk profile of disease-modifying antirheumatic drugs: an update from the RABBIT register]

Related items